

#### Stem Cell Tracking in Neurologic Applications

Jeff W.M. Bulte, Ph.D.

Professor of Radiology, Biomedical Engineering, and Chemical & Biomolecular Engineering

Director, Cellular Imaging Section
Institute for Cell Engineering
The Johns Hopkins University School of Medicine
Baltimore, MD, USA





#### Neural Stem Cell Transplantation: The Case of the Shiverer Dysmyelinated Mouse Brain




90 days, untreated



300 days, stem cell injection


Windrem & Goldman, Cell Stem Cell 2, 553-565 (2008).


## Human fetal glial progenitor cells engrafted at birth into shiverer mice



Mouse survived > 35 weeks (twice normal maximal lifespan)

Windrem & Goldman, Cell Stem Cell 2, 553-565 (2008).





Windrem & Goldman, Cell Stem Cell 2, 553-565 (2008).





# Neurorepair According to an Imaging Scientist





# Molecular and Cellular Imaging Modalities

	Clinical Gen/Cells		Reso lution	Sensit. n cells	Anatomy	Long evity	Reporter gene	Quant.
Optical	endo	no	+++	?	no	+++	yes	no
NIR	no	no	+	?	no	?	no	no
BLI	no	no	+	10,000	no	+++	yes	~yes
PET	yes	yes	+	50,000	no	+/+/+	yes	~yes
Y-rad	yes	yes	++	?	no	+	~~	YES
¹H MRI	yes	yes	++++	1-1000	yes	++	yes	~no
<sup>19</sup> F MRI	no	no	++	7,500	no	++	no	YES
CEST MRI	yes	no	+++	25,000	yes	+++	yes	~yes
X-ray	yes	no	++++	high n	yes	++	no	~yes
US	yes	no	+	1	yes	++	no	~yes




#### **MAGNETIC "DYE"**

Dextran-Coated Superparamagnetic Iron Oxide Particles (SPIO):

Microscopic Magnetic Field Inhomogeneities

Induce Rapid Dephasing of Proton Spins


and Loss of Imaging Signal



LLS size: ~80 nm





# Feridex®: FDA-approved SPIO since 1996 (as Liver Agent, not for Cell Tracking) same as Endorem® in Europe






#### Intracellular Magnetic Labeling using Transfection Agents (i.e., poly-L-lysine)








(anti-dextran immunohistochemistry)




#### MR Imaging of Magnetically Labeled Neural Stem Cells






#### MR Imaging of Magnetically Labeled Neural Stem Cells



P. Walczak et al. MRM 54, 769-774, 2005.



### Routes of Cell Delivery



Stereotactic parenchymal injection

Intravenous infusion

Intraventricular injection






Volume 39, Number 5, May 2008 ISSN 0039-2499 http://stroke.ahajournals.org



American Heart | American Stroke Association Learn and Live»

### Stroke

#### JOURNAL OF THE AMERICAN HEART ASSOCIATION



Targeted Intracarotid Delivery of Magnetically Labeled Mesenchymal Stem Cells

#### ■ Editorials

Leukoaraiosis: Ancient Term to Actual Marker Ultrasound-Enhanced Thrombolysis Balance Between Stroke Prevention and Bleeding Risk in AF

#### ■ Original Contributions Leukoaraiosis and Susceptibility to Infarct Growth

Progression of Small Vessel Disease Unrecognized MI, Dementia, and Small Vessel Disease Stroke and Cognitive Decline After Cardiac Surgery Genome-Wide Linkage Screen for Intracranial Aneurysm Circulating EPC in Acute Stroke Lp-PLA<sub>2</sub> and LysoPC in Symptomatic Carotid Plaques Progression of Intracranial Atherostenosis Microspheres for Sonothrombolysis Sonothrombolysis in MCA Main Stem Occlusion

Microspheres in Brain Vessels Oral Anticoagulation in Atrial Fibrillation Thrombolysis for Cerebral Sinus Thrombosis Thrombosis Caused by Angiography
IV Thrombolysis and Thrombectomy in BAO Intraprocedural Rupture During Aneurysm Treatment fMRI Correlates of Lower Limb Function in Stroke Outcomes in Stroke Structural Brain Changes From CI Therapy After Stroke Psychiatric Morbidity and Return to Work After Stroke Socioeconomic Disparities in Stroke at Old Age MRI of Secondary Thalamic Damage Induced Hypertension in Acute Focal Ischemia Albumin Augments Thrombolysis in Arteriolar Thrombosis T2\*WI Detected Angiogenesis Poststroke in Rats Monitoring Intraarterial Stem Cell Delivery in Stroke Preventing CNS Autoimmunity After Stroke

#### ■ Research Letters

Need for Church-Based Stroke Health Promotion Ischemic Stroke and Chr9p21 Androgen Receptor Variation and Risk of MI and Stroke EPHX2 and Stroke in a Central European Population Carotid Atherosclerosis and Coronary Artery Disease Diabetes and Brain MRI in Vascular Patients Microvascular Imaging Using 7.0T MRA Metabolic Syndrome and Silent Brain Lesions CSF Tenascin-C in Hydrocephalus After SAH Selective MCA Occlusion in a Rabbit Stroke Model Response to IV-tPA in Tandem ICA/MCA Occlusion

#### ■ Special Report

Acute Stroke Imaging Research Roadmap


Topical Review

Hypoxia Imaging in Ischemic Stroke


#### ■ Emerging Therapies Antiplatelet Therapy for Ischemic Stroke ■ Letters to the Editor★

#### ■ AHA/ASA Science Advisory

2D




3D




P. Walczak et al., Stroke, 39, 1569-1574, 2008.



# Our Injection Approach for EAE: Disseminate Cells throughout the entire Neuroaxis



Tx of Feridexlabeled neurospheres at various stages of EAE









Image CNS *in vivo* at 9.4T after cell tx

Days 1, 4, 7, 14, and 28.



#### Tx during Pre-onset of EAE






T. Ben-Hur et. al., Magn. Reson. Med. 57, 164-171 (2007).



### Most migration occurs during the first days after transplantation, and within the first days of clinical disease




Variability at day 6

T. Ben-Hur et. al., Magn. Reson. Med. 57, 164-171 (2007).




### Good correlation between cumulative disease score and distance of MRI migration during the first week post Tx



T. Ben-Hur et. al., Magn. Reson. Med. 57, 164-171 (2007).


### Tx During Chronic Phase of EAE

#### Chronic 2 (ex-vivo MRI and Prussian Blue staining)






### Tx During Acute Phase of EAE




N. Muja, M. Cohen et al.


### Tx During Acute Phase of EAE



#### Tx During Acute Phase of EAE



#### Radial migration along blood vessels





Reca-1 (blood vessel) / anti-BrdU (transplanted neural precursors)



#### Cell-based therapy for neuroimmunological disease

How to most effectively and safely deliver stem cells?








### Exploiting the VLA-4 / VCAM-1 Pathway

(α4β1) VLA-4: Very Late Antigen-4 VCAM: Vascular Cellular Adhesion Molecule

Well-characterized "integrin" system involved in trafficking of leukocytes towards inflammatory sites




### Non-Inflammatory Conditions






### Inflammation





1. Genetic engineering of glial restricted precursor cells (GRPs)

Lentiviral transduction with two vectors, inducing expression of both subunits of VLA-4 integrin




P. Walczak, D.A. Kerr et. al.



#### 2. Magnetic labeling


#### Feridex+PLL





#### 3. LPS treatment or recipient animals


Global induction of endothelial adhesion molecules




P. Walczak, D.A. Kerr et. al.




#### 4. Cannulation of right carotid artery







#### MR monitoring of cell infusion ex vivo






























### Histology after transplantation

#### Ipsilateral hemisphere


#### Contralateral hemisphere



P. Walczak, D.A. Kerr et. al.



#### Enhanced Targeted Delivery of Stem Cells towards Inflammatory Lesions (such as those occurring in MS)



P. Walczak, D.A. Kerr et. al.





### In Vivo MRI Cell Tracking: Clinical Studies

Jeff W. M. Bulte1


**OBJECTIVE.** The purpose of this review is to describe the principles of MRI cell tracking with superparamagnetic iron oxides and the four clinical trials that have been performed.

**CONCLUSION.** Clinical MRI cell tracking is likely to become an important tool at the bedside once (stem) cell therapy becomes mainstream. The most prominent role of this technique probably will be verification of accurate cell delivery with MRI-guided injection, in which interventional radiologists will play a role in the near future. All clinical studies described as of this writing have been performed outside the United States.

Amer. J. Roentgenol. 193, 314-325 (2009).



#### Neural Stem Cell in Brain Trauma Patients (Shanghai)



J. Zhu et al., N. Engl. J. Med. 355, 2376-2378 (2006).

# Clinical experience with the use of Feridex-labeled autologous MSCs in MS patients


D. Karussis, J.W.M. Bulte, T. Ben-Hur et al.,

Arch. Neurol., in press

# Clinical follow up of MS patients following MSC transplantation (6 months)

PTINITIALS	GENDER	AGE	DISEASEDURATION	TYPEOFMS	Initial EDSS	EDSS 1 MONTH	_DSS 3 MONTHS	EDSS 6 MONTHS
П	F	47	12	SP	7.5	6.5	6	6
MH	M	25	14	SP	6	5	3.5	3.5
PD	M	35	13	RP	6.5	5.5	5.5	6
SE	F	36	15	SP	8	7.5	7	7
Al	F	34	8	SP	5.5	4	4.5	5
KE	F	30	5	SP	7	6.5	6.5	6.5
MDC	F	37	9	RP	6.5	6.5	6.5	6.5
ML	F	52	12	SP	7.5	7	7	7.5
SH	M	35	12	RP	7	7	7	7
PM	F	28	10	SP	6.5	5.5	5.5	5
PMT	M	32	10	SP	6	5	4.5	4.5
Ю	M	28	8	SP	8	7.5	7.5	7.5
LZ	F	32	7	PP	4	3.5	3	2
CY	M	52	15	PP	7	7	7	7
TK	M	27	10	SP	7.5	7	7	7
		35.3	10.7		6.7	6.1	5.9	5.9
		8.58	2.97		1.05	1.25	1.41	1.59


# Clinical follow up of MS patients following MSC transplantation (6 months)




### PRE-MSC

### POST MSC






# IV-injected Feridex-labeled MSCs localize in the occipital horns



# IV-injected Feridex-labeled MSCs localize in the spinal cord






"The number one clinical application of MRI cell tracking may not be monitoring cell migration following injection, but rather verifying the actual accuracy of the cell injection itself, at the target side, and then in real time, using MR-guided injectional procedures"



## MR-Guided Real-Time Injections Using MR Compatible Injection Catheters



- Modified loopless antenna design
- Matching, tuning, and decoupling circuitry
- Steerable guide catheter via nitinol pull wire
- 26 gauge nitonol injection needle



# First Clinical Trial Using MR Tracking of Magnetically Labeled Cells

First patient injected on April 26, 2004 (Collaboration between JHU and U of Nijmegen, NL)

ARTICLES

nature biotechnology

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy

I Jolanda M de Vries<sup>1,2</sup>, W Joost Lesterhuis<sup>3</sup>, Jelle O Barentsz<sup>4</sup>, Pauline Verdijk<sup>1</sup>, J Han van Krieken<sup>5</sup>, Otto C Boerman<sup>6</sup>, Wim J G Oyen<sup>6</sup>, Johannes J Bonenkamp<sup>7</sup>, Jan B Boezeman<sup>8</sup>, Gosse J Adema<sup>1</sup>, Jeff W M Bulte<sup>9</sup>, Tom W J Scheenen<sup>4</sup>, Cornelis J A Punt<sup>3</sup>, Arend Heerschap<sup>4</sup> & Carl G Figdor<sup>1</sup>

NATURE BIOTECHNOLOGY VOLUME 23 NUMBER 11 NOVEMBER 2005



#### What Did We Learn:

#### 2) Accidental Misinjection in 4 out of 8 Patients

(Injections performed under US, <u>not</u> MR-Guided)



Pre Post

I. de Vries, et. al., Nat. Biotechnol. 23, 1407-1413 (2005).




# Limitations of Labeling with Exogenous MR Contrast Agents

- -No distinction between live and dead cells
- -Contrast may change over time, affecting interpretation
- -No imaging of cellular differentiation
- -No imaging of rapidly dividing cells



#### Asymmetric Cell Division and Dilution of Feridex Label




P. Walczak et al., MRM 58, 261-269, 2007.




### Reporter Genes



### American Firefly






Photinus pyralis




### BLI - Monitoring of Cell Survival


Evaluating Optimal Immunosuppresive Regimen



## BL Imaging of Survival of Allogeneic Mouse GRPs (*Luc* transgenic fvbn in Balb/c) Grafted in the Corpus Callosum



# BL Imaging of Survival of Allogeneic Mouse GRPs Grafted in the Corpus Callosum






### Imaging Cell Differentiation

GRPs Undifferentiated

GRP-derived Astrocytes





GFAP Immunostaining

BL Imaging
P. Walczak et al.




#### Imaging Cell Differentiation in vivo





# T Cell Imaging with HSV-tk and <sup>18</sup>F-FHBG PET in a Glioma Patient



S.S. Yaghoubi et al., Nat. Clin. Pract. Oncol. 6, 53-58 (2009).



# MRI Reporter Genes: the Holy Grail




NMR IN BIOMEDICINE

NMR Biomed. 2007; **20**: 275–290 Published online in Wiley InterScience (www.interscience.wiley.com) DOI:10.1002/nbm.1134




### Review Article Developing MR reporter genes: promises and pitfalls

Assaf A. Gilad, 1,2† Paul T. Winnard Jr,1† Peter C. M. van Zijl 1,3 and Jeff W. M. Bulte 1,2\*






#### Cloning and Expression of a Lysine Rich Protein (LRP)







#### Imaging of LRP-transfected glioma cells in vivo



**CEST** 






A.A. Gilad et al., Nat. Biotechnol. 25, 217-219 (2007).




## Multiple Colors



# Frequency-dependent CEST MR contrast agents "Multi-color" peptides




M.T. McMahon et. al. Magn. Reson. Med., 60, 803-812 (2008).






#### CEST Sensitivity for Different Peptide Sequences





M.T. McMahon et. al. Magn. Reson. Med., 60, 803-812 (2008).




### Peptide reporters with unique CEST 'codes'







#### CEST RGB 'color'




- $3. \quad (DSSS)_3$
- $4. \quad (DSSSSS)_2$
- 7.  $(DTTTTT)_2$
- 8. (ETT)<sub>4</sub>

- 14. (TTTTK)<sub>2</sub>
- 15.  $(RT)_6$
- 16.  $(RTTT)_3$

G. Liu, M.T. McMahon et. al.




#### <sup>19</sup>F "Hot Spot" MRI Cell Tracking



Jesus Ruiz-Cabello et al., Magn. Reson. Med., 60, 1506-15111 (2008).



#### <sup>19</sup>F "Hot Spot" MRI Cell Tracking



Jesus Ruiz-Cabello et al., Magn. Reson. Med., 60, 1506-15111 (2008).



#### Acknowledgments

Tamir Ben-Hur

Assaf Gilad

Doug Kerr

Heechul Kim

Michael Levy

Guanshu Liu

Michael McMahon

Naser Muja

Piotr Walczak

Peter van Zijl

Supported by 2RO1 NS045062, R21 EB005252, NMSS RG3630.

Dr. Bulte is a paid consultant for SurgiVision Inc.

This arrangement has been approved by the Johns Hopkins University School of Medicine